CID 9916882

Base Information

• Chemical Name: CID 9916882
• CAS No.: 151767-02-1
• Molecular Formula: C35H35ClNNaO3S
• Molecular Weight: 608.177
• Hs Code.: 2933492250
• European Community (EC) Number: 604-813-7
• Mol file: 151767-02-1.mol

Synonyms:Montelukast sodium hydrate;Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-, sodium salt (1:1);SCHEMBL41733;SCHEMBL125179;AKOS037643272

Chemical Property of CID 9916882

Chemical Property:

• Appearance/Colour: White to off-white crystalline powder
• Melting Point: 115 °C(dec.)
• Boiling Point: 750.5 °C at 760 mmHg
• Flash Point: 407.7 °C
• Storage Temp.: -20°C Freezer, Under Inert Atmosphere
• Solubility.: DMSO: ≥8mg/mL at 60°C
• Hydrogen Bond Donor Count: 2
• Hydrogen Bond Acceptor Count: 5
• Rotatable Bond Count: 12
• Exact Mass: 608.2002122
• Heavy Atom Count: 42
• Complexity: 891

Purity/Quality:

98%, ^*data from raw suppliers

MontelukastSodiumSalt ^*data from reagent suppliers

Safty Information:

• Pictogram(s): Xi
• Hazard Codes: Xi
• Statements: 63-41-62
• Safety Statements: 26

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O.[Na]
• Isomeric SMILES: CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O.[Na]
• Uses: It can be applied to alleviate the symptoms caused by allergic rhinitis. A selective leukotriene D4-receptor antagonist. Used as an antiasthmatic antiinfective A potent and highly selective CysLT1 receptor antagonist, without demonstrated CysLT2 activity Montelukast sodium hydrate has been used as a positive control drug to study the protective effects of Gumiganghwal-tang aqueous extract (GGTA) against airway inflammation and pulmonary fibrosis.
• Description: Montelukast was launched as Singulair in Mexico and Finland for the management of mild to moderate asthma inadequately controlled by inhaled corticosteroids and short-acting beta2-agonists. Montelukast can be obtained by an seven-step synthesis from 3-[2(E)-(7-chloroquinolin-2-yl)vinyl] benzaldehyde. Montelukast is a potent, selective and orally active antagonist of the CysLT1 (formerly called LTD4) receptor, thus blocking the effects of the cysteinyl leukotrienes LTC4, LTD4 and LTE4 on microvascular permeability and the activation of eosinophils. Montelukast represents the third molecule of this class which has been approved in asthma after pranlukast (1995) and zafirlukast (1996). Montelukast has been studied extensively in placebo-controlled clinical trials, in mildly or severe asthmatic patients challenged with LTD4 or exercise. A variety of acute bronchoconstricting challenges were inhibited or attenuated with all doses used. Montelukast demonstrated clinically significant improvements in the parameters of asthma control associated with an appreciable improvement in quality of life., reducing days with asthma exacerbations and allowing significant tapering of corticosteroids. Montelukast is well-tolerated and only needs to be administered once a day.
• Therapeutic Function: Anti-asthmatic

Technology Process of CID 9916882

There total 116 articles about CID 9916882 which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 100.0%

montelukast (158966-92-8) → Montelukast sodium (151767-02-1)

Guidance literature:

With sodium hydroxide; In methanol; toluene; at 20 ℃; for 1h;

Reference yield: 99.0%

1-(((1(R)-(3-(2-(7-chloro-2-quinolinil)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropane acetic acid dicyclohexylamine salt (577953-88-9) → Montelukast sodium (151767-02-1)

Guidance literature:

1-(((1(R)-(3-(2-(7-chloro-2-quinolinil)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropane acetic acid dicyclohexylamine salt; With acetic acid; In dichloromethane; pH=4 - 4.5;

With pyrographite; sodium hydroxide; In methanol; water; for 1h;

Reference yield: 99.0%

1-(((1(R)-(3-(2-(7-chloro-2-quinolinil)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropane acetic acid benzylamine salt (1100021-03-1) → Montelukast sodium (151767-02-1)

Guidance literature:

1-(((1(R)-(3-(2-(7-chloro-2-quinolinil)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropane acetic acid benzylamine salt; With acetic acid; In dichloromethane; water; pH=4 - 4.5;

With pyrographite; sodium hydroxide; In methanol; water; for 1h;

upstream raw materials:

sodium hydroxide

montelukast

1-(((1(R)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)-cyclopropaneacetic acid trans-4-aminocyclohexanol salt

1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropaneacetic acid cyclohexylamine salt

Downstream raw materials:

montelukast

2-(1-((((R)-1-(3-((E)-2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propyl)sulfanyl)methyl)cyclopropyl) acetic acid hydrochloride

[R, E]-[[1-[3-[2-(7-chloro-2-quinolinyl)-2-(S)-[(carboxymethyl)cyclopropyl]methyl]thio]ethyl]phenyl]-3-[[[[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-cyclopropane acetic acid

[R, E]-[[1-[3-[2-(7-chloro-2-quinolinyl)-2-(R)-[(carboxymethyl)cyclopropyl]methyl]thio]ethyl]phenyl]-3-[[[[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-cyclopropane acetic acid

Refernces

• 1、 -. "Preparation method of montelukast sodium". Paragraph 0054-0074; 0083-0086. . Retrieved 2020/12/15.
• 2、 -. "A synthesis process of montelukast sodium (by machine translation)". Paragraph 0053-0057. . Retrieved 2019/04/04.